Palvella Therapeutics (PVLA) EBIT Margin (2014 - 2024)
Palvella Therapeutics (PVLA) reported EBIT Margin of 3318.87% for Q1 2024, down 251768.0% year-over-year from N/an in Q2 2023, and down 4276.34% quarter-over-quarter from 75.84% in Q3 2023.
Palvella Therapeutics (PVLA) EBIT Margin (2014 - 2024) Analysis & Trends
Palvella Therapeutics (PVLA) has 11 years of EBIT Margin data on file, last reported at 3318.87% in Q1 2024.
- EBIT Margin for Q1 2024 came in at 3318.87%, down 251768.0% year-over-year; the trailing twelve-month figure through Sep 2024 was 23.41% (up 12236.0% YoY), and the FY2021 annual result was 185.51%, down 6983.0% from the prior year.
- EBIT Margin fell to 3318.87% in Q1 2024 per PVLA's latest filing, from 75.84% in the prior quarter.
- Over five years, EBIT Margin peaked at 10.29% in Q2 2023 and troughed at 4716.28% in Q3 2022.
- A 5-year average of 806.85% and a median of 355.54% in 2022 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2022 and 2023: EBIT Margin sank 403313 bps in 2022, then soared 464044 bps in 2023.
- A 5-year view of EBIT Margin shows it stood at 661.21% in 2020, then surged by 66 bps to 221.53% in 2021, then slumped by 2029 bps to 4716.28% in 2022, then soared by 98 bps to 75.84% in 2023, then tumbled by 4276 bps to 3318.87% in 2024.
- Business Quant data shows PVLA's EBIT Margin at 3318.87% in Q1 2024, 75.84% in Q3 2023, and 10.29% in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Palvella Therapeutics | 1.49 Bn | 1.23 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -3,318.87% |
| Sep 30, 2023 | -75.84% |
| Jun 30, 2023 | 10.29% |
| Mar 31, 2023 | -801.19% |
| Sep 30, 2022 | -4,716.28% |
| Jun 30, 2022 | -355.54% |
| Mar 31, 2022 | -67.86% |
| Dec 31, 2021 | -221.53% |
| Sep 30, 2021 | -683.15% |
| Jun 30, 2021 | -659.88% |
| Mar 31, 2021 | -38.92% |
| Dec 31, 2020 | -661.21% |
| Sep 30, 2020 | -442.29% |
| Jun 30, 2020 | -41.39% |
| Mar 31, 2020 | -29.08% |
| Dec 31, 2019 | -43.52% |
| Sep 30, 2019 | -19.26% |
| Jun 30, 2019 | -229.37% |
| Mar 31, 2019 | -125.02% |
| Dec 31, 2018 | -2,108.00% |